Date: 2017-05-31
Type of information: Research agreement
Compound:
Company: Baxalta (USA - IL) Mayo Clinic (USA - MN)
Therapeutic area: Kidney diseases - Renal diseases
Type agreement: research - R&D
Action mechanism:
Disease:
Details: • On May 31, 2017, Baxter International and Mayo Clinic announced a new research and development collaboration to advance innovation across a spectrum of therapeutic areas where there are high unmet patient needs. The collaboration agreement will bring together the clinical and development expertise at Baxter and Mayo Clinic , where clinicians and researchers will work side-by-side to advance new technologies and therapies that transform patient care. The primary emphasis of the collaboration will be in areas where breakthrough treatment options can be introduced and innovation can drive access to high-quality care. The first project will focus on kidney disease, with additional projects planned in other areas. Approximately 14% of Americans have some degree of chronic kidney disease (CKD), and nearly half also have diabetes and/or cardiovascular disease - the two major causes of CKD. The initial agreement is for a five-year period, with a five-year renewal option. Additional details of the agreement were not disclosed.
Financial terms:
Latest news:
